4D Molecular Therapeutics, Inc (FDMT)

Etorro trading 970x250

About 4D Molecular Therapeutics, Inc

4D Molecular Therapeutics, Inc. operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase I/II clinical trial for the treatment of fabry disease. It also focuses on developing two investigational new drug candidates, which include 4D-150 for the treatment of wet age-related macular degeneration; and 4D-710 for the treatment of cystic fibrosis lung disease. The company was founded in 2013 and is headquartered in Emeryville, California. Address: 5858 Horton Street, EmeryVille, CA, United States, 94608

4D Molecular Therapeutics, Inc News and around…

Latest news about 4D Molecular Therapeutics, Inc (FDMT) common stock and company :

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
26 Oct, 2021 Yahoo! Finance

EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. 4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock offered in the proposed offering. All o

The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
26 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due ...

4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept
26 Oct, 2021 FinancialContent

4D Molecular Therapeutics Inc(NASDAQ: FDMT) hasannounced interim datafrom the Phase 1/2 trial of intravenous 4D-310 ...

4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
25 Oct, 2021 Yahoo! Finance

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution - AGA enzyme activity was within, or significantly above, the normal range in all three patients (up to 25-fold mean normal AGA activity) - 4D-310 had a manageable safety profile and no dose-limiting toxicities - 4D-110 was generally well-tolerated, with initial evidence of clinical activity observed - 4DMT

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
10 Oct, 2021 FinancialContent

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.

4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
10 Oct, 2021 Yahoo! Finance

4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammationClinical activity observed through anatomical measurements of reduced photoreceptor loss in treated vs untreated control eyes on ellipsoid zone area endpointsClinical activity observed through functional improvements in treated vs untreated control eyes on two microperimetry endpoints: (1) mean retinal sensitivity and (2) number of loci with >7 d

4D Molecular Therapeutics Becomes Oversold (FDMT)
08 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

4D Molecular (FDMT) to Start Studies on Cystic Fibrosis, Wet AMD
07 Oct, 2021 Yahoo! Finance

4D Molecular (FDMT) is set to initiate studies for gene-therapy candidates to treat cystic fibrosis lung disease and wet AMD, following FDA clearance of its two IND applications.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

4D Molecular To Test Its Wet AMD Gene Therapy In Patients
06 Oct, 2021 FinancialContent

TheFDA has signed off4D Molecular Therapeutics'(NASDAQ: FDMT) Investigational New Drug Application (IND) for ...

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
06 Oct, 2021 Yahoo! Finance

Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-endEMERYVILLE, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). The active IND enables the initiation

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-710, an A101 Vector-based, Aerosol-delivered Gene Therapy for the Treatment of Cystic Fibrosis Lung Disease
06 Oct, 2021 Yahoo! Finance

Initiation of 4D-710 Phase 1/2 clinical trial sites expected before year-endEMERYVILLE, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for 4D-710 for the treatment of patients with cystic fibrosis. The active IND enables the initiation

Analysts Predict 17% Upside For The Holdings of VHT
01 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $288.57 per unit.

4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference
29 Sep, 2021 FinancialContent
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
24 Sep, 2021 FinancialContent
We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
27 Aug, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights
12 Aug, 2021 FinancialContent
Is 4D Molecular Therapeutics, Inc. (FDMT) A Good Stock To Buy?
26 Jul, 2021 Yahoo! Finance

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the fourth quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Sum Up The Parts: PBSM Could Be Worth $44
12 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.26 per unit.

Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts
28 Jun, 2021 Yahoo! Finance

One thing we could say about the analysts on 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) - they aren't optimistic...

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
25 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

45 Biggest Movers From Yesterday
25 Jun, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced ...

12 Health Care Stocks Moving In Thursday's Intraday Session
24 Jun, 2021 FinancialContent

Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 27.11% to $4.5 during Thursday's regular ...

36 Stocks Moving In Thursday's Mid-Day Session
24 Jun, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) jumped 58% to $2.70 after the company announced it has added the ability to ...

Stocks That Hit 52-Week Lows On Thursday
24 Jun, 2021 FinancialContent

Thursday's morning session saw 8 companies set new 52-week lows. Intriguing Points: The largest company ...

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
24 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for X
24 Jun, 2021 FinancialContent
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
24 Jun, 2021 Yahoo! Finance

4D-110: Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that 4D-110 was well-tolerated and did not result in any dose-limiting toxicity (n=6; all patients followed between one and nine months)4D-125: Initial clinical safety data at both of the two dose levels in the Phase 1 portion of a Phase 1/2 clinical trial indicate that 4D-125 was well-tolerated and did not result in any dose-limiting toxicity (n=6; all patients followed between four and ni

4D Molecular Therapeutics, Inc (FDMT) is a NASDAQ Common Stock listed in , ,

970x250